OPTIC Trial: 3-Year Data Update in CML

Opinion
Video

John C. Molina, MD, EdM, reviews data from the 3-year update from the OPTIC study, and other experts offer their impressions.

Recent Videos
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
Related Content
Genomic subtype was associated with relapse, occurring in nearly 50% of PAX5-altered pediatric acute lymphoblastic leukemia cases.

Comprehensive Childhood ALL Genotyping May Optimize Risk Stratification

Roman Fabbricatore
September 13th 2024
Article

Genomic subtype was associated with relapse, occurring in nearly 50% of PAX5-altered pediatric acute lymphoblastic leukemia cases.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Treatment with CB-012 for patients with relapsed/refractory acute myeloid leukemia is under evaluation as part of the phase 1 AMpLify trial.

CB-012 Earns FDA Fast Track Status in R/R Acute Myeloid Leukemia

Russ Conroy
September 4th 2024
Article

Treatment with CB-012 for patients with relapsed/refractory acute myeloid leukemia is under evaluation as part of the phase 1 AMpLify trial.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia

Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia

Muhammad Hamza Gul, MBBS, MD;Aisha Rehman Siddiqui, MBBS, MD;Farwa Zehra, MBBS;Malaika Rehmani, MBBS;Faraz Waheed, MBBS;Natasha Masood, MBBS;Maleeha Saqib, MBBS;Mahnoor Keen, MBBS, MD;Sharan Siddharth Keshetty, MD;Maham Maqsood, MBBS;Siddharth Arjun Atwal, MD;Muhammad Hamza Sikandari, MBBS;Abdul Baseer Wardak, MBBS
August 19th 2024
Article

Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.

Phase 1/2 AUGMENT-101 study results revealed quick and lasting responses for patients with relapsed/refractory KMT2Ar acute leukemia.

Revumenib Yields High Remission Rates for Acute Leukemia

Roman Fabbricatore
August 16th 2024
Article

Phase 1/2 AUGMENT-101 study results revealed quick and lasting responses for patients with relapsed/refractory KMT2Ar acute leukemia.